Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use
Legend Biotech Corporation - American Depositary Shares (LEGN)
Company Research
Source: GlobeNewswire
Six poster presentations highlight CARVYKTI® efficacy, safety, and real-world outcomes across CARTITUDE trials and analyses, reflecting a maturing and expanding body of evidence SOMERSET, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will present six poster presentations featuring data on CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) at the Tandem Meetings of ASTCT® and CIBMTR®, taking place February 4-7, 2026, in Salt Lake City, UT. With more than 10,000 patients treated worldwide, CARVYKTI® continues to generate a growing body of clinical and real-world evidence, informing how the therapy can be optimally used across the multiple myeloma treatment continuum. These presentations underscore the consistent, durable efficacy and safety of CARVYKTI® across clinical trials and real-world analyses, with outcomes that are particularly compelling when the therapy is used earlier in patients' multip
Show less
Read more
Impact Snapshot
Event Time:
LEGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEGN alerts
High impacting Legend Biotech Corporation - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
LEGN
News
- Legend Biotech (NASDAQ:LEGN) had its price target lowered by analysts at HC Wainwright from $60.00 to $50.00. They now have a "buy" rating on the stock.MarketBeat
- Legend Biotech (NASDAQ:LEGN) was given a new $21.00 price target on by analysts at Jefferies Financial Group Inc..MarketBeat
- Legend Biotech (NASDAQ:LEGN) was downgraded by analysts at TD Cowen from a "buy" rating to a "hold" rating.MarketBeat
- Legend Biotech (NASDAQ:LEGN) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..MarketBeat
- Legend Biotech (NASDAQ:LEGN) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $66.00 price target on the stock.MarketBeat
LEGN
Sec Filings
- 1/21/26 - Form 6-K
- 1/14/26 - Form 6-K
- 1/12/26 - Form 6-K
- LEGN's page on the SEC website